Investor Relations

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer.

We have two small molecule anticancer compounds under evaluation in human clinical trials. Our potential product, Cloretazine® (VNP40101M) is being evaluated for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. Our potential product, Triapine® is under evaluation in clinical studies sponsored by the National Cancer Institute.

We appreciate your interest in our company. Our management and staff are dedicated to one purpose: developing therapeutic drugs for cancer.

Follow the links to learn more about our company and our people, to read our latest news, or to contact us.